Revenue and margins
Revenue was $0. (SEC XBRL company facts, 10-Q, Nov 10, 2026)
The net loss was $20.8M. (SEC XBRL company facts, 10-Q, Nov 10, 2026)
Balance sheet
Cash was $13.8M at Sep 30, 2026, against $11.3M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
Shares outstanding were 188.7 million, against 195.3 million at Jun 30, 2026, a fall of 3.4%. (SEC XBRL company facts, 10-Q, Nov 10, 2026)
At its recent quarterly burn of $14.4M, that cash lasts about 2.9 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
The stock
The Nasdaq screener puts its market value at $481.3M. (Nasdaq stock screener, Nov 13, 2026)
Ovid Therapeutics Inc. puts an S-3 shelf registration on file
On Nov 10, 2026, Ovid Therapeutics Inc. (OVID) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 10, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/OVID)
The filing on SEC EDGAR. (sec.gov)
The filing in the MarginsX reader. (MarginsX reader)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.